230.57
0.23%
+0.53
Biogen Inc (BIIB) 最新ニュース
Biogen Inc. (NASDAQ:BIIB) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Defense World
(BIIB) On The My Stocks Page - Stock Traders Daily
Stock Traders Daily
Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
MarketWatch
Ionis, Biogen Down on Ending Development of ALS Drug - Markets Insider
Markets Insider
Ionis (IONS), Biogen Down on Ending Development of ALS Drug - Zacks Investment Research
Zacks Investment Research
Ionis (IONS), Biogen Down on Ending Development of ALS Drug - Yahoo Finance
Yahoo Finance
Should You Worry About Biogen Inc.'s (NASDAQ:BIIB) CEO Salary Level? - Yahoo New Zealand News
Yahoo New Zealand News
Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone - Scrip
Scrip
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop - Clinical Trials Arena
Clinical Trials Arena
Subcutaneous Maintenance Dosing for Early Alzheimer's Disease Now Under FDA Fast Track Status - Precision Vaccinations
Precision Vaccinations
Biogen, Ionis to discontinue development of experimental ALS drug - Reuters
Reuters
Biogen and Ionis Pharma shares slide as they end development of ALS treatment - MarketWatch
MarketWatch
Biogen also drops collaboration with Ionis on Angelman syndrome candidate - Seeking Alpha
Seeking Alpha
Biogen CEO Looks for Small Deals While Alzheimer's Drug Ramps Up - Bloomberg
Bloomberg
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop - Clinical Trials Arena
Clinical Trials Arena
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To - Benzinga
Benzinga
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop - Pharmaceutical Technology
Pharmaceutical Technology
Biogen and Ionis halt ALS drug development after trial setback - Investing.com
Investing.com
Biogen, Ionis to discontinue development of experimental ALS drug - Reuters
Reuters
Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data - Fierce Biotech
Fierce Biotech
Biogen falls after discontinuing development of ALS drug - XM
XM
Biogen stock Ionis stock drop on ALS setback (NASDAQ:BIIB) - Seeking Alpha
Seeking Alpha
ALS treatment from Biogen, Ionis fails in study - STAT
STAT
ALS treatment from Biogen, Ionis fails in study - STAT
STAT
Readout Newsletter: Biogen, Ionis, Johnson & Johnson news - STAT
STAT
Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis - MarketWatch
MarketWatch
Biogen Shares Update on Angelman Syndrome Program - XM
XM
Biogen, Ionis will discontinue development of their ALS drug - WTVB
WTVB
Biogen, Ionis will discontinue development of their ALS drug - WKZO
WKZO
Biogen, Ionis will discontinue development of their ALS drug - WTAQ
WTAQ
Statement: Biogen Shares Update on Angelman Syndrome Program | Biogen - Biogen
Biogen
Biogen, Ionis to discontinue development of ALS drug - XM
XM
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis - GlobeNewswire
GlobeNewswire
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis - PR Newswire
PR Newswire
Biogen Inc. (NASDAQ:BIIB) Stake Boosted by Private Advisor Group LLC - Defense World
Defense World
Biogen, Ionis to discontinue development of experimental ALS drug - Reuters
Reuters
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
MarketWatch
Biogen Stock Continues Its 24% Sprint On An Alzheimer's Treatment Twist - Investor's Business Daily
Investor's Business Daily
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector - Yahoo Finance
Yahoo Finance
Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA - Reuters
Reuters
Eisai predicts sharp Leqembi sales increase as launch efforts begin to bear fruit - FiercePharma
FiercePharma
Eisai begins FDA submissions for injectable Alzheimer's drug - Seeking Alpha
Seeking Alpha
Eisai, Biogen Launch Rolling BLA for Subcutaneous Alzheimer’s Therapy Leqembi - BioSpace
BioSpace
Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer's drug - PMLiVE
PMLiVE
Eisai begins rolling submission for SC Leqembi - The Pharma Letter
The Pharma Letter
Eisai, Biogen start delayed subcutaneous Leqembi filing - pharmaphorum
pharmaphorum
Eisai And Biogen Fast-Track FDA Approval For A New Alzheimer's Treatment - Finimize
Finimize
After filing hitch, Eisai and Biogen begin rolling FDA submission for subcutaneous Leqembi - FiercePharma
FiercePharma
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
GlobeNewswire Inc.
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous ... - PR Newswire
PR Newswire
大文字化:
|
ボリューム (24 時間):